Arca
Skip to content
Tools
Tools

DNA

Nucleic acid in Human alphaherpesvirus 1 that 2 drugs act on.

  • Drugs that act on it: 2
  • Approved: 2
  • In phases 1 to 3: 0
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on this target, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2

Approved2

  • Trifluridine
  • Idoxuridine

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        TrifluridineApprovedPfizerSmall moleculeInhibitorDNA inhibitor92
        IdoxuridineApprovedGSKSmall moleculeInhibitorDNA inhibitor0

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        Trastuzumab Rezetecan + Bevacizumab vs. TAS-102 + Bevacizumab in Pretreated mCRC With HER2 Low/Moderate Expression or HER2 Positivity With RAS/BRAF MutationTrifluridinePhase 2Not yet recruitingSecond Affiliated Hospital, Zhejiang University, School of MedicineNov 9, 2026
        GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal CancerTrifluridinePhase 3Not yet recruitingGenfleet Therapeutics (Shanghai) Inc.Nov 3, 2026
        A Study of Trifluridine/Tipiracil (TAS-102) Combined With Nedaplatin for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Refractory to ≥ Second-Line ChemotherapyTrifluridinePhase 2Not yet recruitingTao ZhangNov 3, 2026
        Emulation of the SUNLIGHT Trial Using Specialty Oncology Electronic Health Records DatabasesTrifluridine—Active, not recruitingBrigham and Women's HospitalOct 6, 2026
        A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and IrinotecanTrifluridinePhase 3Not yet recruitingSichuan Baili Pharmaceutical Co., Ltd.Jul 28, 2026
        IBI363 Combined With Bevacizumab for Advanced Colorectal CancerTrifluridinePhase 3RecruitingInnovent Biologics (Suzhou) Co. Ltd.Jul 23, 2026
        Nelmastobart in Combination With Tas-102 and Bevacizumab in Recurrent/Metastatic Colorectal CancerTrifluridinePhase 1Not yet recruitingSTCube, Inc.Jun 18, 2026
        EMB-01 in Combination With Chemotherapy for Unresectable or Metastatic Colorectal CancerTrifluridinePhase 1RecruitingShanghai EpimAb Biotherapeutics Co., Ltd.Jun 16, 2026

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2366042, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.